<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:blogger='http://schemas.google.com/blogger/2008' xmlns:georss='http://www.georss.org/georss' xmlns:gd="http://schemas.google.com/g/2005" xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-6822263006341973987</id><updated>2024-09-25T21:47:41.585-07:00</updated><title type='text'>Popular oncology</title><subtitle type='html'></subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default?redirect=false'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><link rel='next' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default?start-index=26&amp;max-results=25&amp;redirect=false'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/15206500601930632914</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>163</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-6768217209615281801</id><published>2008-05-16T09:35:00.000-07:00</published><updated>2008-05-16T09:51:00.700-07:00</updated><title type='text'>Cancer risk in HIV-infected persons</title><content type='html'>&lt;strong&gt;Cancer risk in people infected with human immunodeficiency virus in the United States&lt;/strong&gt;&lt;br /&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;Eric A. Engels (1), Robert J. Biggar (1), H. Irene Hall (2), Helene Cross (3), Allison Crutchfield (4), Jack L. Finch (4), Rebecca Grigg (5),  Timothy S. McNeel (6) et al.    &lt;br /&gt;1) Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD; 2) Centers for Disease Control and Prevention, Atlanta, GA; 3) New Jersey Department of Health and Senior Services, Trenton, NJ; 4) Colorado Department of Public Health, Denver, CO; &lt;/i&gt;&lt;i&gt;5) Florida Department of Health, Tallahassee, FL; &lt;/i&gt;&lt;i&gt;&lt;br /&gt;6) Information Management Services, Incorporated, Silver Spring, MD&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Data are limited regarding cancer risk in human immunodeficiency virus (HIV)-infected persons with modest immunosuppression, before the onset of acquired immunodeficiency syndrome (AIDS).&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;For some cancers, risk may be affected by highly active antiretroviral therapy (HAART) widely available since 1996.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;We linked HIV/AIDS and cancer registries in Colorado, Florida and New Jersey. Standardized incidence ratios (SIRs) compared cancer risk in HIV-infected persons (initially AIDS-free) during the 5-year period after registration with the general population.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Poisson regression was used to compare incidence across subgroups, adjusting for demographic factors. Among 57,350 HIV-infected persons registered during 1991-2002 (median CD4 count 491 cells/mm3), 871 cancers occurred during follow-up. Risk was elevated for Kaposi sarcoma (KS, SIR 1,300 [n = 173 cases]), non-Hodgkin lymphoma (NHL, 7.3 [n = 203]), cervical cancer (2.9 [n = 28]) and several non-AIDS-defining malignancies, including Hodgkin lymphoma (5.6 [n = 36]) and cancers of the lung (2.6 [n = 109]) and liver (2.7 [n = 14]). KS and NHL incidence declined over time but nonetheless remained elevated in 1996-2002. Incidence increased in 1996-2002 compared to 1991-1995 for Hodgkin lymphoma (relative risk 2.7, 95%CI 1.0-7.1) and liver cancer (relative risk infinite, one-sided 95%CI 1.1-infinity). Non-AIDS-defining cancers comprised 31.4% of cancers in 1991-1995, versus 58.0% in 1996-2002. For KS and NHL, risk was inversely related to CD4 count, but these associations attenuated after 1996.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;We conclude that KS and NHL incidence declined markedly in recent years, likely reflecting HAART-related improvements in immunity, while incidence of some non-AIDS-defining cancers increased. These trends have led to a shift in the spectrum of cancer among HIV-infected persons.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Keywords:&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;HIV/AIDS • epidemiology • Kaposi sarcoma • non-Hodgkin lymphoma • Hodgkin lymphoma • liver cancer • lung cancer&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;International Journal of Cancer, Apr 2008&lt;br /&gt;Volume 123, Issue 1 , Pages 187 - 194&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/6768217209615281801/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/6768217209615281801' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/6768217209615281801'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/6768217209615281801'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2008/05/cancer-risk-in-hiv-infected-persons.html' title='Cancer risk in HIV-infected persons'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/15206500601930632914</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-2179832474822924939</id><published>2008-04-16T09:22:00.000-07:00</published><updated>2008-04-16T09:42:27.529-07:00</updated><title type='text'>Cancer cells like sugar</title><content type='html'>&lt;strong&gt;A potential sugar fix for tumors&lt;/strong&gt;&lt;br /&gt;&lt;span&gt;&lt;div align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Researchers at the Duke School of Medicine apparently have solved the riddle of why cancer cells like sugar so much, and it may be a mechanism that could lead to better cancer treatments.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Jonathan Coloff, a graduate student in Assistant Professor Jeffrey Rathmell&#39;s laboratory in the Duke Department of Pharmacology and Cancer Biology, has found that the tumor cells use glucose sugar as a way to avoid programmed cell death. They make use of a protein called Akt, which promotes glucose metabolism, which in turn regulates a family of proteins critical for cell survival, the researchers shared during an April 15 presentation at the American Association of Cancer Research Annual Meeting in San Diego.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;i&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;In normal cells, growth factors regulate metabolism and cell survival. Removing these factors leads to loss of glucose uptake and metabolism and cell death. Cancer cells, however, maintain glucose metabolism and resist cell death, even when deprived of growth factors.&lt;/span&gt;&lt;/i&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;To study how Akt might affect these processes, Coloff and colleagues introduced a cancer-causing form of Akt called myrAkt, into cells that depend on growth factor to survive. The mutant form of Akt allowed cells to maintain glucose usage and survive even when no growth factors were present, allowing them to bypass a normal safeguard used by cells to prevent cancer development.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;The death of normal cells after growth factors are removed is partly accomplished by two proteins called Mcl-1 and Puma. But the cancer-causing version of Akt prevents these two proteins from accomplishing their tasks, allowing the cell to survive when it shouldn&#39;t.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Once glucose was withdrawn from the environment, however, Akt was no longer able to maintain regulation of the key targeted proteins Mcl-1 and Puma, and the cells died.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&quot;Akt&#39;s dependence on glucose to provide an anti-cell-death signal could be a sign of metabolic addiction to glucose in cancer cells, and could give us a new avenue for a metabolic treatment of cancer,&quot; said Dr. Rathmell.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Duke University Medical Center, April 16, 2008&lt;/span&gt;&lt;/div&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;span style=&quot;color:#000099;&quot;&gt;http://www.brightsurf.com/news/headlines/37172/A_potential_sugar_fix_for_tumors.html&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/2179832474822924939/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/2179832474822924939' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/2179832474822924939'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/2179832474822924939'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2008/04/cancer-cells-like-sugar.html' title='Cancer cells like sugar'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-2207076650897033843</id><published>2008-04-03T05:04:00.000-07:00</published><updated>2008-04-03T05:06:30.572-07:00</updated><title type='text'>New method to test for lung cancer</title><content type='html'>&lt;strong&gt;Researchers develop new method to test for lung cancer&lt;/strong&gt;&lt;br /&gt;&lt;span&gt;&lt;div align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Researchers from Boston University School of Medicine have developed a new &quot;clinicogenomic model&quot; to accurately test for lung cancer. The model combines a specific gene expression for lung cancer as well as clinical risk factors. These findings currently appear on-line in the journal Cancer Prevention Research.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Lung cancer is the leading cause of cancer death in the United States and the world, with more than one million deaths worldwide annually. Eighty-five to 90 percent of subjects with lung cancer in the United States are current or former smokers with 10 to 20 percent of heavy smokers developing this disease.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;A previous study by the same researchers reported a gene expression biomarker capable of distinguishing cytologically normal large airway epithelial cells from smokers with and without lung cancer. However, the biomarker has limited sensitivity depending on the stage and the location of the cancer.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Studying current and former smokers undergoing bronchoscopies for suspicion of lung cancer, the researchers compared the likelihood of the subjects having lung cancer using the biomarker, the clinical risk factors and a combination of the two -- clinicogenomic model. They found patients using the clinicogenomic model had increased sensitivity, specificity, positive value and negative predictive value of their cancer compared to the other methods.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&quot;Our data suggests that the clinicogenomic model might serve to identify patients who would benefit from further invasive testing, thereby expediting the diagnosis and treatment for their malignancy,&quot; said senior author Avrum Spira, MD, an assistant professor of medicine and pathology at Boston University School of Medicine.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;According to the researchers, it is hoped this prediction model will expedite more invasive testing and appropriate therapies for smokers with lung cancer as well as reduce invasive diagnostic procedures for individuals without lung cancer.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Boston University, April 02, 2008&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;span style=&quot;color:#000099;&quot;&gt;http://www.brightsurf.com/news/&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/2207076650897033843/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/2207076650897033843' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/2207076650897033843'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/2207076650897033843'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2008/04/new-method-to-test-for-lung-cancer.html' title='New method to test for lung cancer'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-2682375990170866829</id><published>2008-03-12T02:11:00.000-07:00</published><updated>2008-03-12T02:14:24.918-07:00</updated><title type='text'>Prostate cancer and risk of heart disease death</title><content type='html'>&lt;strong&gt;Prostate cancer therapy linked to increased risk of heart disease death&lt;/strong&gt;&lt;br /&gt;&lt;span&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;The use of androgen deprivation therapy to treat localized prostate cancer is associated with an increased risk of death from heart disease, according to a study published online October 9 in the Journal of the National Cancer Institute.&lt;br /&gt;&lt;br /&gt;Androgen deprivation therapy is frequently used to treat high-risk localized prostate cancer. Studies have shown that androgen deprivation therapy, when used with external beam radiation therapy, improves survival in patients with advanced and localized prostate cancer. But the use of androgen deprivation therapy can also lead to the development of metabolic syndrome, which increases the risk of type II diabetes or coronary artery disease.&lt;br /&gt;&lt;br /&gt;Henry Tsai, M.D., of Harvard Medical School in Boston and colleagues investigated whether androgen deprivation therapy increases the risk of death from heart disease in patients treated for localized prostate cancer. They collected data on 3,262 patients treated by surgical removal of the prostate and 1,630 patients treated with certain radiation therapies or cryotherapy (in which the tumor tissue is frozen to kill the cells). Of these patients, about 1,000 were also treated with androgen deprivation therapy.&lt;br /&gt;&lt;br /&gt;After a median follow-up of nearly 4 years, 131 patients died of heart disease. Both androgen deprivation therapy and older age were associated with an increased risk of death from heart disease. Among men 65 years and older who had their prostates removed, the 5-year incidence of heart disease-related death was 5.5 percent for those receiving androgen deprivation, and 2 percent among those who did not. For men younger than 65 years, the rates were also increased, 3.6 percent and 1.2 percent respectively. There was also an increased risk of death in men who received androgen deprivation in addition to radiation or cryotherapy, but it was not statistically significant.&lt;br /&gt;&lt;br /&gt;&quot;The results of this study and others support the view that use of [androgen deprivation therapy] may contribute to death from cardiovascular causes and underscore the importance of careful cardiovascular evaluation and intervention before initiating [androgen deprivation therapy] in patients with localized prostate cancer,&quot; the authors write.&lt;br /&gt;&lt;br /&gt;In an accompanying editorial, Jerome Seidenfeld, Ph.D, of the Blue Cross and Blue Shield Association in Chicago and colleagues explain that the design of the study makes it difficult to conclude whether androgen deprivation therapy caused the increase in deaths from heart disease. They point out that it is unlikely that androgen deprivation therapy would have these effects only in men whose prostates were removed but not those treated with radiation and other methods.&lt;br /&gt;&lt;br /&gt;&quot;The article by Tsai [and colleagues] has raised an interesting hypothesis, but patients and clinicians need better risk estimates for cardiovascular death associated with [androgen deprivation therapy] use that are based on randomized trials rather than retrospective analysis,&quot; the editorialists write.&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;/span&gt;&lt;strong&gt;&lt;span&gt;&lt;br /&gt;&lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;strong&gt;&lt;span&gt;Journal of the National Cancer Institute,&lt;/span&gt;&lt;/strong&gt;&lt;span&gt;&lt;strong&gt; &lt;/strong&gt;October 10, 2007&lt;/span&gt;&lt;strong&gt;&lt;span&gt;&lt;br /&gt;http://www.brightsurf.com/news/&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/2682375990170866829/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/2682375990170866829' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/2682375990170866829'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/2682375990170866829'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2008/03/prostate-cancer-and-risk-of-heart.html' title='Prostate cancer and risk of heart disease death'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-3138433124837197602</id><published>2008-02-25T02:30:00.000-08:00</published><updated>2008-02-25T02:34:42.864-08:00</updated><title type='text'>New in methods of detection of ovarian cancer</title><content type='html'>&lt;strong&gt;New developments in biomarkers for epithelial ovarian cancer&lt;/strong&gt;&lt;br /&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;div align=&quot;justify&quot;&gt;&lt;br /&gt;With the genomic revolution radical improvement has been made in methods of detection of ovarian cancer. This is of the utmost importance, since the chances of successful treatment are strongly enhanced with early detection. In a special issue of Disease Markers, published by IOS Press, eleven articles explore new developments in the identification and understanding of biomarkers for epithelial ovarian cancer.&lt;br /&gt;&lt;br /&gt;&quot;Many of these biomarkers may serve not only as markers of clinical and biology interest but also as potential therapeutic and imaging targets which could significantly improve the survival of patients with this disease,&quot; states Prof. Michael J. Birrer (National Cancer Institute, Center for Cancer Research, Cell and Cancer Biology Department, MD, USA).&lt;br /&gt;&lt;br /&gt;Discussed in the issue are new hypotheses on the molecular development of ovarian cancer, SP markers of risk, biomarkers that are specific for the different histological subtypes, and new biomarkers and approaches for the early detection of ovarian cancer. Furthermore, new molecular technologies have allowed for the analysis and characterization of specific cellular components of ovarian tumors identifying biomarkers of tumor associated immune and endothelial cells.&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;span style=&quot;color:#3333ff;&quot;&gt;IOS Press, &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color:#3333ff;&quot;&gt;November 30, 2007&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;span style=&quot;color:#000099;&quot;&gt;http://www.brightsurf.com/news/headlines/34494/New_developments_in_biomarkers_for_epithelial_ovarian_cancer.html&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/3138433124837197602/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/3138433124837197602' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/3138433124837197602'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/3138433124837197602'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2008/02/new-in-methods-of-detection-of-ovarian.html' title='New in methods of detection of ovarian cancer'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-8837242244730142</id><published>2008-02-15T02:15:00.000-08:00</published><updated>2008-02-15T02:26:52.329-08:00</updated><title type='text'>Stop smoking and diminish alcohol consumption</title><content type='html'>&lt;div align=&quot;center&quot;&gt;&lt;a onblur=&quot;try {parent.deselectBloggerImageGracefully();} catch(e) {}&quot; href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhqwwiVCcig61RY22OEejbZr-mQsZbKPeOkW3A5eIrIjiFcwtrzzqkTJ3Z40A9G_azZwkccSR2L0oS5IzPnJZwJC4fvbGPls7RUpDjLLT6ai6z7O7gP2NlVH1K2olr6O54oBEFVkkbZQvQ/s1600-h/3885625290.jpg&quot;&gt;&lt;img src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhqwwiVCcig61RY22OEejbZr-mQsZbKPeOkW3A5eIrIjiFcwtrzzqkTJ3Z40A9G_azZwkccSR2L0oS5IzPnJZwJC4fvbGPls7RUpDjLLT6ai6z7O7gP2NlVH1K2olr6O54oBEFVkkbZQvQ/s200/3885625290.jpg&quot; border=&quot;0&quot; alt=&quot;&quot; id=&quot;BLOGGER_PHOTO_ID_5167151167568282050&quot; /&gt;&lt;/a&gt;&lt;br /&gt;&lt;div align=&quot;left&quot;&gt;&lt;strong&gt;The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma&lt;/strong&gt;&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;color:#666666;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Renato Talamini (1), Jerry Polesel(1), Michele Spina(2), Emanuela Chimienti(2), Diego Serraino(1), Antonella Zucchetto(1), Ernesto Zanet(2), Silvia Franceschi(3), Umberto Tirelli(2)&lt;br /&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;color:#666666;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;1) Unit of Epidemiology and Biostatistics, National Cancer Institute, Aviano, Italy; 2) Division of Medical Oncology A, National Cancer Institute, Aviano, Italy; 3) International Agency For Research On Cancer, Lyon, France&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;br /&gt;Tobacco smoking and alcohol consumption have not been clearly related to the risk of non-Hodgkin lymphoma (NHL), and the impact of these two factors on survival of NHL patients has received little attention.&lt;br /&gt;Cases were 268 subjects with incident histologically-confirmed NHL, admitted as inpatients to the Division of Medical Oncology, between 1983 and 2002. These individuals were enrolled as cases in case-control studies conducted at the same institution over the same period. For all patients clinical (histological subtype, major prognostic factors and treatment) and epidemiological data (smoking and drinking habits) were available. Survival analysis was performed using Kaplan-Meier methods. Hazard ratio (HR) was estimated by Cox proportional hazard model. Compared to never smokers, patients who smoked  20 cigarettes/day had higher risks of death (HR = 1.70, 95% confidence interval (CI): 1.06-2.73) and lower survivals at 5 years (60 and 46%, respectively). Likewise, patients who drunk  4 drinks/day showed 1.69-fold higher probability of death (95% CI: 1.04-2.76) in comparison to drinkers of &lt;2 drinks/day (5-year survival: 47 and 67%, respectively). When combining exposure to alcohol and tobacco, no excess of death emerged in light drinkers (&lt;4 drinks/day), irrespective of their smoking habits, but higher risks of death emerged among heavy drinkers.&lt;br /&gt;In the present study, heavy tobacco smoking, and particularly, heavy alcohol drinking were associated with poor survival in NHL patients.&lt;br /&gt;&lt;strong&gt;Our findings strongly encourage physicians to advice NHL patients to stop smoking and diminish alcohol consumption to obtain improvements in the course of NHL.&lt;/strong&gt; &lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;div align=&quot;left&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;span style=&quot;color:#3333ff;&quot;&gt;International Journal of Cancer Volume 122, Issue 7 , Pages 1624 - 1629&lt;/span&gt;&lt;br /&gt;&lt;div align=&quot;left&quot;&gt;&lt;span style=&quot;color:#000099;&quot;&gt;http://www3.interscience.wiley.com/cgi-bin/abstract/117356350/ABSTRACT&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/8837242244730142/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/8837242244730142' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/8837242244730142'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/8837242244730142'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2008/02/stop-smoking-and-diminish-alcohol.html' title='Stop smoking and diminish alcohol consumption'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhqwwiVCcig61RY22OEejbZr-mQsZbKPeOkW3A5eIrIjiFcwtrzzqkTJ3Z40A9G_azZwkccSR2L0oS5IzPnJZwJC4fvbGPls7RUpDjLLT6ai6z7O7gP2NlVH1K2olr6O54oBEFVkkbZQvQ/s72-c/3885625290.jpg" height="72" width="72"/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-435082351253153747</id><published>2008-02-06T04:36:00.000-08:00</published><updated>2008-02-06T04:38:49.263-08:00</updated><title type='text'>Prognostic potential of Tissue factor</title><content type='html'>&lt;strong&gt;Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer&lt;/strong&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;color:#666666;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Geneviève Patry, Hélène Hovington, Hélène Larue, François Harel, Yves Fradet, Louis Lacombe&lt;br /&gt;Centre de recherche en cancérologie de l&#39;Université Laval, CHUQ, L&#39;Hôtel-Dieu de Québec, QC&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;Tissue factor (TF), a transmembrane glycoprotein responsible for initiating the extrinsic pathway of blood coagulation plays a key role in cancer growth, metastasis and angiogenesis. Various studies have demonstrated the prognostic potential of TF expression in several cancers. However, its role in bladder cancer is unclear.&lt;br /&gt;&lt;br /&gt;This study evaluated the prognostic potential of TF expression in muscle-invasive bladder tumors from patients treated with radical cystectomies. Immunohistochemical staining using a monoclonal antibody (mAb) anti-TF was carried out on sections of tissue microarray blocks containing cores of muscle-invasive bladder tumors (4 cores/tumor) from 218 patients. The intensity of the staining was evaluated on a scale from 0 to 3 by two independent observers who were both unaware of the clinicopathological characteristics of the samples. TF was expressed in 77.6% of tumors, independently from baseline characteristics (age, gender, stage and grade) as assessed using the  2 and Student t tests. During follow-up (median: 2.6 years), 45.4% of the patients died from the progression of their cancer. Kaplan-Meier survival showed that among the 103 patients with node-negative (N0) transitional cell carcinoma (TCC), those with TF-positive tumors had shorter bladder cancer-specific survival (p = 0.0276). Moreover, multivariate Cox regression analysis showed they had a 3.15-fold greater risk of dying from bladder cancer (95% CI: 1.1-9.0; p = 0.032).&lt;br /&gt;&lt;br /&gt;In conclusion, TF expression was an independent predictor of disease-specific survival in N0 muscle-invasive TCCs treated by radical cystectomy and therefore, might help identify patients at higher risk of disease progression. These patients could potentially benefit from adjuvant chemotherapy.&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;KEYWORDS: bladder cancer • cystectomy • tissue factor • prognostic factor&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;color:#3333ff;&quot;&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;strong&gt;International Journal of Cancer&lt;br /&gt;Volume 122, Issue 7 , Pages 1592 – 1597&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/435082351253153747/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/435082351253153747' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/435082351253153747'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/435082351253153747'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2008/02/prognostic-potential-of-tissue-factor.html' title='Prognostic potential of Tissue factor'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-5767462057961166568</id><published>2008-02-04T01:45:00.000-08:00</published><updated>2008-02-04T02:01:16.904-08:00</updated><title type='text'>Strategies for prostate cancer screening</title><content type='html'>&lt;div align=&quot;left&quot;&gt;&lt;strong&gt;The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy&lt;/strong&gt;&lt;br /&gt;&lt;/div&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;color:#666666;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Andrew J. Vickers (1,2,3), David Ulmert (4,5), Angel M. Serio (1,2,3), Thomas Björk (4,5), Peter T. Scardino (1,2,3), James A. Eastham (1,2,3), Göran Berglund (4,5), Hans Lilja (1,2,3,4,5)&lt;br /&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;color:#666666;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;1) Department of Surgery (Urology), Memorial Sloan-Kettering Cancer Center, New York, NY; 2) Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, New York, NY; 3) Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY; 4) Department of Laboratory Medicine, Lund University, University Hospital UMAS, Malmö, Sweden; 5) Department of Clinical Sciences, Lund University, University Hospital UMAS, Malmö, Sweden&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;br /&gt;Both benign and malignant prostate diseases elevate total prostate-specific antigen (tPSA), and the incidence of benign disease increases markedly with age.&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;There is evidence, however, that free-to-total PSA ratio (%fPSA) and human kallikrein 2 (hK2) more closely reflect the malignant process.&lt;br /&gt;We tested the hypothesis that tPSA levels are more strongly predictive of cancer in younger when compared to older men, whereas %fPSA and hK2 are more strongly predictive in men tested closer to diagnosis.&lt;br /&gt;The study included 13,676 men age  44 in Sweden, where PSA screening was uncommon during the study period. fPSA, tPSA and hK2 were measured in archived plasma collected during 1974-1986 in 501 men subsequently diagnosed with prostate cancer up to 1999 and in 1,292 matched controls.&lt;br /&gt;The predictive value of tPSA was lower in older men (p = 0.003) but was not strongly affected by time to diagnosis (p = 0.3); the predictive value of hK2 was higher closer to diagnosis (p &lt; 0.0005) but was not modified by age (p = 0.7). A model including tPSA, fPSA and hK2 was superior (p = 0.02) to tPSA alone in older (AUC 0.819 vs. 0.794), but not in younger men (0.758 vs. 0.759). Total PSA can be used as a single marker at early middle age to predict long-term risk of prostate cancer and thus to determine intensity of subsequent screening. In contrast, %fPSA and hK2 add important predictive value in older men and much closer to diagnosis.&lt;br /&gt;&lt;/div&gt;Strategies for prostate cancer screening should be based on thorough understanding of the interaction of kallikrein-related biomarkers with prostate pathobiology.&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;color:#000099;&quot;&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;strong&gt;KEYWORDS: &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;prostate cancer • prediction • detection • prostate specific antigen&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;color:#000099;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;International Journal of Cancer&lt;br /&gt;Volume 121, Issue 10 , Pages 2212 – 2217&lt;br /&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;span style=&quot;color:#000066;&quot;&gt;http://www3.interscience.wiley.com/cgi-bin/abstract/114297273/ABSTRACT&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/5767462057961166568/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/5767462057961166568' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/5767462057961166568'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/5767462057961166568'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2008/02/strategies-for-prostate-cancer.html' title='Strategies for prostate cancer screening'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-1629993749657114653</id><published>2008-01-08T02:39:00.000-08:00</published><updated>2008-01-08T02:40:55.278-08:00</updated><title type='text'>Christmas Blessings for all!</title><content type='html'>&lt;div align=&quot;center&quot;&gt;&lt;a onblur=&quot;try {parent.deselectBloggerImageGracefully();} catch(e) {}&quot; href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiJhCn5-fIU-Ztanu-xTAVhMYSMdxcbjaIYaG-i2o56M06cP-MeE3Jq5QSCxQSOEd2k-lUREJlfpqPKGf5aUSZTM4pzTk3t5OGldbITY0F5wKI58B8YDHpzwBDEDWiH5fzSa25WRwU7hTA/s1600-h/рождество1.jpg&quot;&gt;&lt;img src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiJhCn5-fIU-Ztanu-xTAVhMYSMdxcbjaIYaG-i2o56M06cP-MeE3Jq5QSCxQSOEd2k-lUREJlfpqPKGf5aUSZTM4pzTk3t5OGldbITY0F5wKI58B8YDHpzwBDEDWiH5fzSa25WRwU7hTA/s320/рождество1.jpg&quot; border=&quot;0&quot; alt=&quot;&quot; id=&quot;BLOGGER_PHOTO_ID_5153053793751568530&quot; /&gt;&lt;br /&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style=&quot;color:#3333ff;&quot;&gt;Christmas Blessings for all!&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/1629993749657114653/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/1629993749657114653' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/1629993749657114653'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/1629993749657114653'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2008/01/christmas-blessings-for-all.html' title='Christmas Blessings for all!'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiJhCn5-fIU-Ztanu-xTAVhMYSMdxcbjaIYaG-i2o56M06cP-MeE3Jq5QSCxQSOEd2k-lUREJlfpqPKGf5aUSZTM4pzTk3t5OGldbITY0F5wKI58B8YDHpzwBDEDWiH5fzSa25WRwU7hTA/s1600/рождество1.jpg" height="72" width="72"/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-6581368213728046431</id><published>2007-12-02T11:13:00.000-08:00</published><updated>2007-12-02T11:17:57.854-08:00</updated><title type='text'>Alcohol and risk of colorectal cancer</title><content type='html'>&lt;strong&gt;Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition &lt;/strong&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;Alcohol consumption may be associated with risk of colorectal cancer (CRC), but the epidemiological evidence for an association with specific anatomical subsites, types of alcoholic beverages and current vs. lifetime alcohol intake is inconsistent.&lt;br /&gt;Within the European Prospective Investigation into Cancer and Nutrition (EPIC), 478,732 study subjects free of cancer at enrolment between 1992 and 2000 were followed up for an average of 6.2 years, during which 1,833 CRC cases were observed.&lt;br /&gt;Detailed information on consumption of alcoholic beverages at baseline (all cases) and during lifetime (1,447 CRC cases, 69% of the cohort) was collected from questionnaires. Cox proportional hazard models were used to examine the alcohol-CRC association. After adjustment for potential confounding factors, lifetime alcohol intake was significantly positively associated to CRC risk (hazard ratio, HR = 1.08, 95%CI = 1.04-1.12 for 15 g/day increase), with higher cancer risks observed in the rectum (HR = 1.12, 95%CI = 1.06-1.18) than distal colon (HR = 1.08, 95%CI = 1.01-1.16), and proximal colon (HR = 1.02, 95%CI = 0.92-1.12).&lt;br /&gt;Similar results were observed for baseline alcohol intake. When assessed by alcoholic beverages at baseline, the CRC risk for beer (HR = 1.38, 95%CI = 1.08-1.77 for 20-39.9 vs. 0.1-2.9 g/day) was higher than wine (HR = 1.21, 95%CI = 1.02-1.44), although the two risk estimates were not significantly different from each other.&lt;br /&gt;Higher HRs for baseline alcohol were observed for low levels of folate intake (1.13, 95%CI = 1.06-1.20 for 15 g/day increase) compared to high folate intake (1.03, 95%CI = 0.98-1.09).&lt;br /&gt;In this large European cohort, both lifetime and baseline alcohol consumption increase colon and rectum cancer risk, with more apparent risk increases for alcohol intakes greater than 30 g/day.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;color:#000099;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;International Journal of Cancer&lt;br /&gt; Volume 121, Issue 9, Pages 2065 - 2072 (1 November 2007)&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/6581368213728046431/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/6581368213728046431' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/6581368213728046431'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/6581368213728046431'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/12/alcohol-and-risk-of-colorectal-cancer.html' title='Alcohol and risk of colorectal cancer'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-4279735127357881222</id><published>2007-11-16T02:38:00.000-08:00</published><updated>2007-11-16T02:40:31.048-08:00</updated><title type='text'>Childhood cancer: Epidemiology</title><content type='html'>&lt;strong&gt;New malignancies following childhood cancer in the United States, 1973-2002&lt;/strong&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;color:#333333;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;Peter D. Inskip, Rochelle E. Curtis&lt;br /&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;color:#333333;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;br /&gt;The objectives of our study were to quantify risks for developing new malignancies among childhood cancer survivors, identify links between particular types of first and subsequent cancer, and evaluate the possible role of treatment.&lt;br /&gt;A cohort of 25,965 2-month survivors of childhood cancer diagnosed in the U.S. during 1973-2002 was identified and followed through SEER cancer registries. Observed-to-expected ratios (O/E) were calculated, and Poisson regression was used to compare risks among treatment groups. Childhood cancer survivors were at nearly 6-fold risk of developing a new cancer relative to the general population (O/E = 5.9, 95% CI: 5.4-6.5). Most common were subsequent primary cancers of the female breast, central nervous system, bone, thyroid gland and soft tissue, as well as cutaneous melanoma and acute non-lymphocytic leukemia (ANLL).&lt;br /&gt;The greatest risks of subsequent cancers occurred among patients diagnosed previously with Hodgkin lymphoma (HL), Ewing sarcoma, primitive neuroectodermal tumor, or retinoblastoma. Risk of subsequent solid cancers was higher among persons whose initial treatment for childhood cancer included radiotherapy, whereas the excess of subsequent ANLL was strongly related to chemotherapy. The O/E for subsequent ANLL increased with increasing calendar year of initial cancer diagnosis among survivors of cancers other than HL, most likely due to increasing use of leukemogenic drugs for solid cancers and non-Hodgkin lymphoma.&lt;br /&gt;Childhood cancer survivors are at markedly increased risk of developing a variety of new cancers relative to the general population, but the magnitude of excess risk and specific types of second cancer vary widely by type of first cancer.&lt;br /&gt;&lt;br /&gt;Keywords: second cancers • multiple primary cancers • childhood cancer • epidemiology • surveillance, epidemiology and end results (SEER) registries&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;color:#000099;&quot;&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;strong&gt;International Journal of Cancer&lt;br /&gt;Volume 121, Issue 10 , Pages 2233 – 2240 (15 November 2007)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/4279735127357881222/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/4279735127357881222' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/4279735127357881222'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/4279735127357881222'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/11/childhood-cancer-epidemiology.html' title='Childhood cancer: Epidemiology'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-7547223665159714609</id><published>2007-11-08T03:44:00.000-08:00</published><updated>2007-11-08T04:07:01.303-08:00</updated><title type='text'>Estrogen and breast cancer</title><content type='html'>&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjd0wj2LTCHZWziYjF7IjzAsYOJoNM8on7DgSc-QtkPPRUMeovdFtF6gc6l6Na62lX1FCl9oeB2-J8lxu3T2i4l3nOrrIUKS_opjKHEKjKh8VCUziH1tR9v-KsgND1rNdPtzOrSHk6FdqU/s1600-h/estrogen+.jpeg&quot;&gt;&lt;img id=&quot;BLOGGER_PHOTO_ID_5130435485431204818&quot; alt=&quot;&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjd0wj2LTCHZWziYjF7IjzAsYOJoNM8on7DgSc-QtkPPRUMeovdFtF6gc6l6Na62lX1FCl9oeB2-J8lxu3T2i4l3nOrrIUKS_opjKHEKjKh8VCUziH1tR9v-KsgND1rNdPtzOrSHk6FdqU/s200/estrogen+.jpeg&quot; border=&quot;0&quot; /&gt;&lt;/a&gt;&lt;strong&gt;New link between estrogen and breast cancer&lt;/strong&gt;&lt;br /&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;The female sex hormone estrogen turns on a gene linked to breast cancer, according to new research by Brisbane scientists.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;The cancer biology team from UQ&#39;s Diamantina Institute for Cancer, Immunology and Metabolic Medicine, believe their finding will help explain the link between breast cancer and high levels of estrogen.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&quot;What we&#39;ve shown is that the ability of estrogen to switch this gene on is important for the growth of breast cancer cells,&quot; Diamantina cancer biology research leader Professor Tom Gonda said.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;The gene they studied, known as MYB, is found in about 70 percent of all breast cancers and is one of several dozen genes called oncogenes that promote cancer growth.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&quot;What&#39;s important in breast cancer is the ability of estrogen to turn on MYB rather than there being a mutation in the gene itself,&quot; Professor Gonda said.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;He said the next step was to take the results, which come from isolated cancer cells grown in the laboratory, and test them in laboratory mice that are a better model for human patients.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&quot;We&#39;re trying to show directly that MYB can induce cancerous changes in normal breast cells.&quot;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Professor Gonda and his colleagues at UQ worked with researchers in Melbourne, Adelaide and the United States and published their findings this month in the prestigious scientific journal Proceedings of the National Academy of Sciences of the USA.&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;He said a drug that blocks the action of MYB might be used to treat breast cancer in the future but he warned that would take many years of hard work.&lt;/span&gt;&lt;/div&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;div&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;August 27, 2007&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;Research Australia&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div&gt;&lt;a href=&quot;http://www.brightsurf.com/news/headlines/32474/New_link_between_estrogen_and_breast_cancer.html&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;http://www.brightsurf.com/news/headlines/32474/New_link_between_estrogen_and_breast_cancer.html&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/7547223665159714609/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/7547223665159714609' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/7547223665159714609'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/7547223665159714609'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/11/new-link-between-estrogen-and-breast.html' title='Estrogen and breast cancer'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjd0wj2LTCHZWziYjF7IjzAsYOJoNM8on7DgSc-QtkPPRUMeovdFtF6gc6l6Na62lX1FCl9oeB2-J8lxu3T2i4l3nOrrIUKS_opjKHEKjKh8VCUziH1tR9v-KsgND1rNdPtzOrSHk6FdqU/s72-c/estrogen+.jpeg" height="72" width="72"/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-8505390738581561758</id><published>2007-11-08T03:39:00.000-08:00</published><updated>2007-11-08T03:44:15.650-08:00</updated><title type='text'>Breast asymmetry</title><content type='html'>&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjDLwYEL2oun6Wf_zqhMz7cuGzzLH0OoNK4czbu0Lsy5u0Z2UlNtA5q9xKcp-LqncDQWg-964RJqtQ5wnI26ETZ-PL_o6YYnNC12e1MER1Ar0G4dEfYjyhR5sFrtRLhJ-tAHCy3QG7ggsQ/s1600-h/asymmetry+.jpeg&quot;&gt;&lt;img id=&quot;BLOGGER_PHOTO_ID_5130433939242978242&quot; style=&quot;FLOAT: right; MARGIN: 0px 0px 10px 10px; CURSOR: hand&quot; alt=&quot;&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjDLwYEL2oun6Wf_zqhMz7cuGzzLH0OoNK4czbu0Lsy5u0Z2UlNtA5q9xKcp-LqncDQWg-964RJqtQ5wnI26ETZ-PL_o6YYnNC12e1MER1Ar0G4dEfYjyhR5sFrtRLhJ-tAHCy3QG7ggsQ/s200/asymmetry+.jpeg&quot; border=&quot;0&quot; /&gt;&lt;/a&gt;&lt;strong&gt;Breast asymmetry predicts breast cancer&lt;/strong&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;br /&gt;Women who go on to develop breast cancer tend to have breasts that are less symmetrical than women who don&#39;t develop the cancer. A study published today in Breast Cancer Research reveals that breast asymmetry could be a reliable independent predictor of breast cancer. The study found that the relative odds of developing breast cancer increased by 1.5 with each 100ml increase in breast asymmetry.&lt;br /&gt;Diane Scutt from the University of Liverpool, UK and colleagues studied the mammograms of 252 women who did not have breast cancer at the time of the mammography, but later on developed the disease. The control group consisted of 252 women matched for age who underwent mammography at the same time, but did not develop breast cancer.&lt;br /&gt;Scutt et al.&#39;s results show that, at the time the mammography was done, women who went on to develop breast cancer had higher breast volume asymmetry than controls. The authors found that the relative odds of breast cancer increased by 1.5 for a 100ml increase in absolute breast volume asymmetry, after adjusting for other potential risk factors. They conclude that breast asymmetry is a significant independent predictor of breast cancer, and could be a reliable indicator of future breast disease.&lt;/div&gt;&lt;br /&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;March 20, 2006&lt;br /&gt;BioMed Central&lt;/div&gt;&lt;div&gt;&lt;a href=&quot;http://www.brightsurf.com/news/headlines/23509/Breast_asymmetry_predicts_breast_cancer.html&quot;&gt;http://www.brightsurf.com/news/headlines/23509/Breast_asymmetry_predicts_breast_cancer.html&lt;/a&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/8505390738581561758/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/8505390738581561758' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/8505390738581561758'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/8505390738581561758'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/11/breast-asymmetry.html' title='Breast asymmetry'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjDLwYEL2oun6Wf_zqhMz7cuGzzLH0OoNK4czbu0Lsy5u0Z2UlNtA5q9xKcp-LqncDQWg-964RJqtQ5wnI26ETZ-PL_o6YYnNC12e1MER1Ar0G4dEfYjyhR5sFrtRLhJ-tAHCy3QG7ggsQ/s72-c/asymmetry+.jpeg" height="72" width="72"/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-517947264739231731</id><published>2007-11-08T03:35:00.000-08:00</published><updated>2007-11-08T03:39:06.237-08:00</updated><title type='text'>Ovarian cancer: Regular medical care</title><content type='html'>&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjwNWBV6-wEYtCDes4MiibwVck9oUKrTwnJNzmaeKm2Xs9v_fgVaii4MxxTL0Nfi4YLKGCHtQWs-wytxeiDaSgEEhrkLaYzUQXG8HGFhxd-7nenkXLGRIDzxKbfozEatdSEORTErGPBjBQ/s1600-h/Women&quot;&gt;&lt;img id=&quot;BLOGGER_PHOTO_ID_5130432362989980594&quot; style=&quot;FLOAT: right; MARGIN: 0px 0px 10px 10px; CURSOR: hand&quot; alt=&quot;&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjwNWBV6-wEYtCDes4MiibwVck9oUKrTwnJNzmaeKm2Xs9v_fgVaii4MxxTL0Nfi4YLKGCHtQWs-wytxeiDaSgEEhrkLaYzUQXG8HGFhxd-7nenkXLGRIDzxKbfozEatdSEORTErGPBjBQ/s200/Women&#39;s+Lifetime+Risk.jpeg&quot; border=&quot;0&quot; /&gt;&lt;/a&gt;&lt;strong&gt;Women without regular medical care at increased risk of ovarian cancer&lt;/strong&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;In North America, ovarian cancer is the second most common gynecological cancer and is the leading cause of death among women with gynecological cancer. The high mortality is in part due to the difficulty of detecting and diagnosing this condition at an early stage.&lt;br /&gt;In this case-control study, Abenhaim and colleagues examined whether the frequency of medical visits and pelvic examinations and the type of health care provider visited had an effect on the risk of ovarian cancer. They found that women who did not have an annual medical visit or pelvic examination and who had no regular health care provider were at an increased risk of ovarian cancer. This risk was most pronounced among postmenopausal women. Although the study could not determine whether women who sought regular health care and had a regular physician were at a decreased risk of ovarian cancer, the most prudent recommendation is that women, especially those who are postmenopausal, should be encouraged to maintain regular health care.&lt;/span&gt;&lt;/div&gt;&lt;br /&gt;&lt;div&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;March 27, 2007&lt;br /&gt;&lt;strong&gt;Canadian Medical Association Journal&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;a href=&quot;http://www.brightsurf.com/news/&quot;&gt;&lt;strong&gt;http://www.brightsurf.com/news/&lt;/strong&gt;&lt;/a&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/517947264739231731/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/517947264739231731' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/517947264739231731'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/517947264739231731'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/11/women-without-regular-medical-care-at.html' title='Ovarian cancer: Regular medical care'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjwNWBV6-wEYtCDes4MiibwVck9oUKrTwnJNzmaeKm2Xs9v_fgVaii4MxxTL0Nfi4YLKGCHtQWs-wytxeiDaSgEEhrkLaYzUQXG8HGFhxd-7nenkXLGRIDzxKbfozEatdSEORTErGPBjBQ/s72-c/Women&#39;s+Lifetime+Risk.jpeg" height="72" width="72"/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-1561925183900612858</id><published>2007-11-07T06:44:00.000-08:00</published><updated>2007-11-07T06:48:30.413-08:00</updated><title type='text'>Coffee, tea, milk, soda and juice and renal cell cancer</title><content type='html'>&lt;strong&gt;Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies&lt;/strong&gt;&lt;br /&gt;&lt;strong&gt;&lt;/strong&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;Specific beverage intake may be associated with the risk of renal cell cancer through a diluting effect of carcinogens, alterations of hormone levels, or other changes in the renal tubular environment, but few prospective studies have examined these associations. &lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;We evaluated the associations between coffee, tea, milk, soda and fruit and vegetable juice intakes and renal cell cancer risk in a pooled analysis of 13 prospective studies (530,469 women and 244,483 men). Participants completed a validated food-frequency questionnaire at baseline. &lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;Using the primary data, the study-specific relative risks (RRs) were calculated and then pooled using a random effects model. A total of 1,478 incident renal cell cancer cases were identified during a follow-up of 7-20 years across studies. &lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;Coffee consumption was associated with a modestly lower risk of renal cell cancer (pooled multivariate RR for 3 or more 8 oz (237 ml) cups/day versus less than one 8 oz (237 ml) cup/day = 0.84; 95% CI = 0.67-1.05; p value, test for trend = 0.22). &lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;Tea consumption was also inversely associated with renal cell cancer risk (pooled multivariate RR for 1 or more 8 oz (237 ml) cups/day versus nondrinkers = 0.85; 95% CI = 0.71-1.02; pvalue, test for trend = 0.04). &lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;No clear associations were observed for milk, soda or juice. &lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;Our findings provide strong evidence that neither coffee nor tea consumption increases renal cell cancer risk. Instead, greater consumption of coffee and tea may be associated with a lower risk of renal cell cancer.&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt; &lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&lt;strong&gt;International Journal of Cancer&lt;br /&gt;Volume 121, Issue 10 , Pages 2246 – 2253 (15 November 2007)&lt;/strong&gt;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&lt;a href=&quot;http://www3.interscience.wiley.com/cgi-bin/abstract/114281867/ABSTRACT&quot;&gt;&lt;strong&gt;http://www3.interscience.wiley.com/cgi-bin/abstract/114281867/ABSTRACT&lt;/strong&gt;&lt;/a&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/1561925183900612858/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/1561925183900612858' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/1561925183900612858'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/1561925183900612858'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/11/coffee-tea-milk-soda-and-juice-and.html' title='Coffee, tea, milk, soda and juice and renal cell cancer'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-6586113152714290192</id><published>2007-10-29T06:52:00.000-07:00</published><updated>2007-10-29T06:54:44.938-07:00</updated><title type='text'>Flavonoids may reduce ovarian cancer risk</title><content type='html'>&lt;strong&gt;A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer&lt;/strong&gt;&lt;br /&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;div align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;span style=&quot;color:#333333;&quot;&gt;&lt;i&gt;Margaret A. Gates (1, 2), Shelley S. Tworoger (1, 2), Jonathan L. Hecht (3), Immaculata De Vivo (1, 2), Bernard Rosner (1, 4), Susan E. Hankinson (1, 2)&lt;br /&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;1) Channing Laboratory, Department of Medicine, Brigham and Women&#39;s Hospital and Harvard Medical School, Boston, MA; 2) Department of Epidemiology, Harvard School of Public Health, Boston, MA; 3) Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; 4) Department of Biostatistics, Harvard School of Public Health, Boston, MA&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;Flavonoids are antioxidant compounds found in plants, including fruits, vegetables and tea. No prior prospective studies have examined the association between intake of flavonoids in the flavonol and flavone subclasses and ovarian cancer risk.&lt;br /&gt;We analyzed the association between intake of 5 common dietary flavonoids and incidence of epithelial ovarian cancer among 66,940 women in the Nurses&#39; Health Study. We calculated each participant&#39;s intake of myricetin, kaempferol, quercetin, luteolin and apigenin from dietary data collected at multiple time points, and used Cox proportional hazards regression to model the incidence rate ratio (RR) of ovarian cancer for each quintile of intake. Our analysis included 347 cases diagnosed between 1984 and 2002, and 950,347 person-years of follow-up. There was no clear association between total intake of the 5 flavonoids examined and incidence of ovarian cancer (RR = 0.75 for the highest versus lowest quintile, 95% confidence interval [CI] = 0.51-1.09).&lt;br /&gt;However, there was a significant 40% decrease in ovarian cancer incidence for the highest versus lowest quintile of kaempferol intake (RR = 0.60, 95% CI = 0.42-0.87; p-trend = 0.002), and a significant 34% decrease in incidence for the highest versus lowest quintile of luteolin intake (RR = 0.66, 95% CI = 0.49-0.91; p-trend = 0.01). There was evidence of an inverse association with consumption of tea (nonherbal) and broccoli, the primary contributors to kaempferol intake in our population.&lt;br /&gt;These data suggest that dietary intake of certain flavonoids may reduce ovarian cancer risk, although additional prospective studies are needed to further evaluate this association. If confirmed, these results would provide an important target for ovarian cancer prevention.&lt;br /&gt;&lt;/div&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;span style=&quot;color:#000099;&quot;&gt;&lt;br /&gt;http://www3.interscience.wiley.com/cgi-bin/abstract/114230474/ABSTRACT&lt;/span&gt;&lt;br /&gt;International Journal of Cancer&lt;br /&gt;Volume 121, Issue 10 , Pages 2225 – 2232 (15 November 2007)&lt;br /&gt;© 2007 Wiley-Liss, Inc.&lt;/span&gt;&lt;/strong&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/6586113152714290192/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/6586113152714290192' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/6586113152714290192'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/6586113152714290192'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/10/flavonoids-may-reduce-ovarian-cancer.html' title='Flavonoids may reduce ovarian cancer risk'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-3265265932281076431</id><published>2007-10-29T06:41:00.000-07:00</published><updated>2007-10-29T06:46:54.269-07:00</updated><title type='text'>Pancreas cancer risk and Alergy</title><content type='html'>&lt;strong&gt;Allergies are associated with reduced pancreas cancer risk:&lt;br /&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;A population-based case-control study in Ontario, Canada&lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;color:#333333;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Ayelet Eppel (1), Michelle Cotterchio (2, 3), Steven Gallinger (1, 4)&lt;br /&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;color:#333333;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;1) Familial Gastrointestinal Cancer Registry, Digestive Diseases Clinical Research Centre, Joseph and Wolf Lebovic Centre, Mount Sinai Hospital, Toronto, Ontario, Canada; 2) Department of Public Health Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; 3) Division of Preventive Oncology, Cancer Care Ontario, Toronto, Ontario, Canada; 4) Department of Surgery, Faculty of Medicine, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;Pancreatic adenocarcinoma is one of the deadliest cancers with mortality rates almost equaling incidence rates. Each year, approximately 3,500 Canadians are diagnosed with this disease.&lt;br /&gt;Although somewhat inconsistent, epidemiological studies have found that allergies are associated with a reduced pancreas cancer risk while there appears to be no association with asthma. These associations were evaluated in a population-based case-control study conducted in Ontario. Incident cases of pancreatic adenocarcinoma, identified through the Ontario Cancer Registry (OCR), and diagnosed April 1, 2003 to June 1, 2006, were recruited by the Ontario Pancreas Cancer Study (OPCS). Controls were recruited from the Ontario Familial Colorectal Cancer Registry (OFCCR). Data on 276 cases and 378 controls were available for the current study. Multivariable logistic regression analysis was used to obtain age-adjusted odds ratio (AOR) estimates. Ever having allergies or hayfever was associated with reduced pancreas cancer risk (OR = 0.43, 95% confidence interval (CI): 0.29-0.63). There was no association observed between a history of asthma and pancreas cancer risk. Findings are of great importance to understanding the biological mechanisms involved in pancreas cancer development.&lt;br /&gt;&lt;/div&gt;Keywords: allergy and immunology • asthma • case-control studies • hypersensitivity • pancreatic neoplasms&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;span style=&quot;color:#000099;&quot;&gt;http://www3.interscience.wiley.com/cgi-bin/abstract/114281139/ABSTRACT&lt;/span&gt;&lt;br /&gt;International Journal of Cancer&lt;br /&gt;Volume 121, Issue 10 , Pages 2241 – 2245 (15 November 2007)&lt;br /&gt;© 2007 Wiley-Liss, Inc.&lt;/span&gt;&lt;/strong&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/3265265932281076431/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/3265265932281076431' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/3265265932281076431'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/3265265932281076431'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/10/pancreas-cancer-risk-and-alergy.html' title='Pancreas cancer risk and Alergy'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-4889991506966313239</id><published>2007-10-26T01:51:00.000-07:00</published><updated>2007-10-26T02:03:10.800-07:00</updated><title type='text'>Lung cancer - Resistant to chemotherapy</title><content type='html'>&lt;strong&gt;Resistance to chemotherapy in lung cancer, optimizing flu vaccination strategies&lt;/strong&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;Lung cancer is the most common cause of cancer-related death worldwide, in part because these tumors often are or become resistant to chemotherapy. A study by Shyam Biswal and colleagues, published in the international open-access journal PLoS Medicine, now shines some light on what causes this resistance.&lt;br /&gt;&lt;br /&gt;Cancer cells acquire resistance by making high levels of proteins that destroy chemotherapeutic agents (detoxification enzymes) or pump them out of cells (efflux pumps), and by making antioxidants that protect cells against the oxidative damage caused by some chemotherapy drugs. All of those proteins have normal functions as well; they protect cells from environmental toxins and from oxidants produced by the chemical processes of life.&lt;br /&gt;&lt;br /&gt;Their production is regulated by NRF2, a transcription factor (a protein that controls the expression of other proteins) that is in turn controlled by a protein called KEAP1. Biswal and colleagues investigated whether changes in KEAP1 might underlie the drug resistance seen in many lung cancers. The researchers examined the KEAP1 gene in tissue taken from lung tumors and in several lung cancer cell lines and found mutations in KEAP1 in half the cell lines and a fifth of the tumor samples. They also found that about half of the samples had lost one copy of the KEAP1 gene-cells usually have two copies of each gene. Five of the six tumors with KEAP1 mutations had lost the other (functional) copy of KEAP1-geneticists call this biallelic inactivation-leaving them without any functional KEAP1.&lt;br /&gt;&lt;br /&gt;As would be expected, the tumor cells had more NRF2 than normal cells and also made more detoxification enzymes, efflux proteins, and antioxidants than normal cells. And Biswal and colleagues showed that lung cancer cells with KEAP1 mutations were more resistant to chemotherapy drugs than normal lung cells.&lt;br /&gt;&lt;br /&gt;These results indicate that biallelic inactivation of KEAP1 is a frequent genetic alteration in lung cancer and suggest that the loss of KEAP1 activity is one way that lung tumors can increase their NRF2 activity and develop resistance to chemotherapeutic drugs. If other studies confirm that high NRF2 activity is associated with a poor response to chemotherapy, then the development of NRF2 inhibitors might help to improve treatment outcomes in patients with chemotherapy-resistant tumors.&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;br /&gt;Public Library of Science&lt;br /&gt;&lt;span style=&quot;color:#000099;&quot;&gt;http://www.brightsurf.com/news/&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/4889991506966313239/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/4889991506966313239' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/4889991506966313239'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/4889991506966313239'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/10/lung-cancer-resistant-to-chemotherapy.html' title='Lung cancer - Resistant to chemotherapy'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-5314104937261116192</id><published>2007-10-26T01:23:00.000-07:00</published><updated>2007-10-26T01:27:27.140-07:00</updated><title type='text'>Strategies for prostate cancer screening</title><content type='html'>&lt;strong&gt;The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: &lt;span style=&quot;font-size:85%;&quot;&gt;Towards a biologically-based screening strategy&lt;/span&gt;&lt;/strong&gt;&lt;br /&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;color:#333333;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Andrew J. Vickers (1, 2, 3), David Ulmert (4, 5), Angel M. Serio (1, 2, 3), Thomas Björk (4, 5), Peter T. Scardino &lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;(1, 2, 3)&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;, James A. Eastham &lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;(1, 2, 3)&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;, Göran Berglund (4, 5), Hans Lilja (1, 2, 3, 4, 5)&lt;br /&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;color:#333333;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;1) Department of Surgery (Urology), Memorial Sloan-Kettering Cancer Center, New York, NY; 2) Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, New York, NY; 3) Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY; 4) Department of Laboratory Medicine, Lund University, University Hospital UMAS, Malmö, Sweden; 5) Department of Clinical Sciences, Lund University, University Hospital UMAS, Malmö, Sweden&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;br /&gt;Both benign and malignant prostate diseases elevate total prostate-specific antigen (tPSA), and the incidence of benign disease increases markedly with age.&lt;br /&gt;There is evidence, however, that free-to-total PSA ratio (%fPSA) and human kallikrein 2 (hK2) more closely reflect the malignant process.&lt;br /&gt;We tested the hypothesis that tPSA levels are more strongly predictive of cancer in younger when compared to older men, whereas %fPSA and hK2 are more strongly predictive in men tested closer to diagnosis.&lt;br /&gt;The study included 13,676 men age  44 in Sweden, where PSA screening was uncommon during the study period. fPSA, tPSA and hK2 were measured in archived plasma collected during 1974-1986 in 501 men subsequently diagnosed with prostate cancer up to 1999 and in 1,292 matched controls.&lt;br /&gt;The predictive value of tPSA was lower in older men (p = 0.003) but was not strongly affected by time to diagnosis (p = 0.3); the predictive value of hK2 was higher closer to diagnosis (p &lt; 0.0005) but was not modified by age (p = 0.7). A model including tPSA, fPSA and hK2 was superior (p = 0.02) to tPSA alone in older (AUC 0.819 vs. 0.794), but not in younger men (0.758 vs. 0.759).&lt;br /&gt;Total PSA can be used as a single marker at early middle age to predict long-term risk of prostate cancer and thus to determine intensity of subsequent screening.&lt;br /&gt;In contrast, %fPSA and hK2 add important predictive value in older men and much closer to diagnosis.&lt;br /&gt;Strategies for prostate cancer screening should be based on thorough understanding of the interaction of kallikrein-related biomarkers with prostate pathobiology.&lt;br /&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;color:#000099;&quot;&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;strong&gt;International Journal of Cancer&lt;br /&gt;Volume 121, Issue 10 , Pages 2212 – 2217 (15 November 2007)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;strong&gt;&lt;br /&gt;© 2007 Wiley-Liss, Inc.&lt;/strong&gt;&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/5314104937261116192/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/5314104937261116192' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/5314104937261116192'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/5314104937261116192'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/10/strategies-for-prostate-cancer.html' title='Strategies for prostate cancer screening'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-8507529881904537008</id><published>2007-10-19T03:31:00.000-07:00</published><updated>2007-10-19T03:34:11.477-07:00</updated><title type='text'>Lycopene - reduced risk of prostate cancer</title><content type='html'>&lt;strong&gt;Lycopene slows human prostate tumour growth in mice and combining it with vitamin E is even better&lt;/strong&gt;&lt;br /&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;A study by Dutch and German researchers has provided evidence that lycopene may be able to inhibit the growth of prostate tumours and that its effect may be enhanced if it is combined with vitamin E.&lt;br /&gt;&lt;br /&gt;A number of epidemiological studies have already indicated that high intake of lycopene - a carotinoid that gives the red colour to tomatoes and other fruits - is associated with a reduced risk of prostate cancer.&lt;br /&gt;&lt;br /&gt;But, these observational findings have now been underpinned by new research demonstrating a beneficial effect in human prostate tumours grown in mice. A Phase II study testing the compounds in cancer patients is now under way.&lt;br /&gt;&lt;br /&gt;The findings of the animal study are being reported by Dutch research scientist Dr. Jacqueline Limpens at the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva.&lt;br /&gt;&lt;br /&gt;The study involved testing one low and one high dose of synthetic lycopene alone, one low and one high dose of synthetic vitamin E alone and a combination of low dose synthetic lycopene and vitamin E or a placebo. The researchers injected human tumour cells into the prostate of mice to see what effect the lycopene and vitamin supplements would have on the tumour growth and PSA (prostate specific antigen)[2] and to compare any effects against the placebo.&lt;br /&gt;&lt;br /&gt;Dr. Limpens, who is from the Department of Urology at the Josephine Nefkins Institute at the Erasmus Medical Center in Rotterdam, said: &quot;We found that low dose lycopene suppressed the growth of the human prostate tumours by over half (at day 42 of the study), extending the tumour doubling time accordingly, while all other single treatments had no significant effect. However, the combination of low-dose lycopene and vitamin E produced the greatest tumour inhibition - 73% (at day 42). Importantly, we also saw that the doubling time of PSA values matched the tumour responses in all the experimental groups. This means that we can use PSA values as a surrogate marker in short phase II/III human trials as it is clear that PSA values are accurately reflecting the inhibiting activity of the lycopene and vitamin E on tumour growth.&lt;br /&gt;&lt;br /&gt;&quot;What was particularly marked was that it was the low dose of both lycopene and vitamin E that was the most effective, demonstrating that &#39;more does not necessarily equal better&#39;. Many pharmacological agents and natural compounds follow a bell-shaped dose response curve, which means that very low or high doses may not work and that there is an optimal dose between the two extremes.&quot;&lt;br /&gt;&lt;br /&gt;The study showed that the lycopene and vitamin E were effectively taken up in the mice prostates in the same form as they are in humans, said Dr. Limpens.&lt;br /&gt;&lt;br /&gt;Dr. Limpens said the findings seem promising, but it was early days yet and the Phase II trial in Germany was designed to verify whether a similar treatment to that used in the mice could alter the course of minimal clinical disease in patients. The lycopene product used (LycoVit®)[3], has received the Generally Recognized as Safe (GRAS) status from the United States Food and Drug Administration (FDA) and can be used to fortify foods.&lt;br /&gt;&lt;br /&gt;It was too early, said Dr. Limpens, to say whether lycopene and vitamin E could ever be used to prevent prostate cancer in healthy individuals. The first step was to see the results from the studies on men with prostate cancer: changes may, for example, be necessary to optimise the treatment. And before any preventative trials could even be considered it would be essential to verify the compound&#39;s potential to really prevent the development of cancer in a mouse model.&lt;br /&gt;&lt;br /&gt;&quot;However, our data fit in with the general picture that lycopene and vitamin E may have chemopreventative effects on prostate cancer. Therefore we would certainly recommend that all men regularly eat lycopene and vitamin E-rich foods: for example, all kinds of processed tomato products, papayas, pink grapefruit and watermelon, wheat germs, whole grains, mangoes, leafy green vegetables, nuts and olive oils. Of course, this needs to be part of an all-round healthy lifestyle and diet with plenty of vegetables and other healthy foods. Regular consumption of supplements and fortified foods may help to obtain adequate amounts of lycopene and vitamin E, which may otherwise be difficult to obtain while maintaining a balanced diet.&quot;&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;&lt;br /&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color:#000099;&quot;&gt;http://www.brightsurf.com/news/&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/8507529881904537008/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/8507529881904537008' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/8507529881904537008'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/8507529881904537008'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/10/lycopene-reduced-risk-of-prostate.html' title='Lycopene - reduced risk of prostate cancer'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-5030830773555702310</id><published>2007-09-27T02:06:00.000-07:00</published><updated>2007-09-27T02:10:38.506-07:00</updated><title type='text'>Antioxidants: Prevent prostate cancer</title><content type='html'>&lt;strong&gt;Prevent prostate cancer with antioxidants? Gene pathway may reveal more clues&lt;/strong&gt;&lt;br /&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;div align=&quot;justify&quot;&gt;&lt;br /&gt;Scientists from Maryland and New Jersey have identified a molecular pathway in mice that makes prostate cells vulnerable to cancer-causing oxygen damage. The pathway, which is also involved in human prostate cancer, may help determine how and whether antioxidants, such as certain vitamins or their products that reverse the damage, can prevent prostate cancer.&lt;br /&gt;&lt;br /&gt;The researchers, from Johns Hopkins Kimmel Cancer Center and The Cancer Institute of New Jersey, found that when the tumor suppressor gene Nkx3.1 malfunctions, prostate cells lose the ability to protect themselves from oxygen damage. Results of the new studies are in the August issue of the journal Cancer Research.&lt;br /&gt;&lt;br /&gt;&quot;Normally, cells with functioning Nkx3.1 seem to process oxidative free radicals appropriately,&quot; says Theodore L. DeWeese, M.D., a co-author of the study and director of the Department of Radiation Oncology &amp;amp; Molecular Radiation Sciences at Hopkins. &quot;But cells with faulty Nkx3.1 genes cannot manage oxidative injury. Then, their DNA gets damaged, and that leads to other mutations that in turn can bring about cancer.&quot;&lt;br /&gt;&lt;br /&gt;The researchers specifically found that a key role of Nkx3.1 is to prevent oxidative damage by regulating the expression of other genes. Oxygen causes cellular degeneration through so-called oxidative free radicals -- highly reactive atoms with an unpaired electron that can rip through cells like a bullet. Free radicals are produced as a result of normal body metabolism, and are widely known to be intimately involved in aging, as well as cancer development.&lt;br /&gt;&lt;br /&gt;&quot;Our findings provide new insights regarding the relationship between loss of protection against oxidative stress and the initiation of prostate cancer,&quot; adds Cory Abate-Shen, Ph.D., senior study author and professor of medicine and neuroscience, member at the Center for Biotechnology and Medicine at UMDNJ-Robert Wood Johnson Medical School. &quot;One key finding is that defects in the oxidative response pathway occur early in prostate cancer development.&quot; Abate-Shen also is co-director of the Prostate Cancer Program at the Cancer Institute of New Jersey.&lt;br /&gt;&lt;br /&gt;For the study, the researchers used a sophisticated computer technique called gene expression profiling to compare in-depth the genetic makeup of mice whose Nkx3.1 gene was disrupted with that of normal mice. The method takes all DNA from the cells and allows scientists to look for aberrations. DeWeese likens it to studying thousands of pages of an encyclopedia simultaneously; trying to identify what pages may have been altered.&lt;br /&gt;&lt;br /&gt;They observed that mice with malfunctioning Nkx3.1 incorrectly expressed 638 genes, including those that created a significant reduction in some antioxidant enzymes vital to oxidative damage prevention. These alterations occurred in mice as early as four months of age-well before cellular changes are visible in the mouse prostate. The mutant mice also displayed a fivefold increase in the amount of cancer-related DNA damage, called 8-hydroxy-2&#39;-deoxyguanosine.&lt;br /&gt;&lt;br /&gt;Further investigation showed that the progression to prostate cancer as it occurs in mice lacking Nkx3.1 and another tumor suppressor, Pten, correlated with additional deregulation of antioxidants and more profound accumulations of oxidative damage to DNA and protein.&lt;br /&gt;&lt;br /&gt;Prostate cancer is the most commonly diagnosed cancer in men and ranks second to lung cancer as the leading cause of cancer death among American men. More than 232,000 cases of prostate cancer are diagnosed and treated annually in the United States, and close to 30,000 men die each year of the disease. Most men over the age of 50 will have some experience with prostate disease - with either an enlarged prostate or cancer.&lt;/div&gt;&lt;/span&gt;&lt;br /&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;Cancer Institute of New Jersey&lt;br /&gt;&lt;span style=&quot;color:#000099;&quot;&gt;http://www.brightsurf.com/news/&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/5030830773555702310/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/5030830773555702310' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/5030830773555702310'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/5030830773555702310'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/09/antioxidants-prevent-prostate-cancer.html' title='Antioxidants: Prevent prostate cancer'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-3251846624293119876</id><published>2007-09-21T01:15:00.000-07:00</published><updated>2007-09-21T01:20:57.890-07:00</updated><title type='text'>Breast cancer: Effect of actein</title><content type='html'>&lt;strong&gt;The growth inhibitory effect of actein  on human breast cancer cells is associated with activation of stress response pathways&lt;/strong&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;color:#666666;&quot;&gt;&lt;span&gt;&lt;i&gt;&lt;span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Linda Saxe Einbond (1), Tao Su (2), Hsan-au Wu (1), Richard Friedman (2), Xiaomei Wang (2), Alejandro Ramirez (1), Fredi Kronenberg (1), I. Bernard Weinstein (2)&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;color:#666666;&quot;&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;span&gt;&lt;i&gt;&lt;span&gt; &lt;br /&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span&gt;&lt;i&gt;&lt;span&gt;1) Department of Rehabilitation Medicine, Columbia University College of Physicians and Surgeons, New York, NY; 2) Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, NY&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;span&gt;Previous studies indicate that the triterpene glycoside actein from the herb black cohosh inhibits growth of human breast cancer cells.&lt;br /&gt;This study seeks to identify genes altered in human breast cancer cells by treatment with actein, using gene expression analysis. We treated MDA-MB-453 human breast cancer cells with actein at 2 doses, 20 or 40 µg/mL, for 6 or 24 hr.&lt;br /&gt;We identified 5 genes that were activated after each of the treatments that are known to play a role in cellular responses to diverse stresses, including the DNA damage and unfolded protein responses. In addition, four genes that mediate the integrated stress response (ISR), including activating transcription factor 4, were induced under at least one of the 4 treatment conditions.&lt;br /&gt;We used hierarchical clustering to define clusters comprising patterns of gene expression. Two ISR genes, activating transcription factor 3 (ATF3) and DNA damage- inducible transcript 3, and lipid biosynthetic genes were activated after exposure to actein at 40 µg/mL for 6 hr, whereas the cell cycle genes cyclin E2 and cell division cycle 25A were repressed.&lt;br /&gt;Our results suggest that actein induces 2 phases of the ISR, the survival phase and the apoptotic phase, depending on the dose and duration of treatment. We confirmed the results of gene expression analysis with real-time RT-PCR for 18 selected genes and Western blot analysis for ATF3. Since actein activated transcription factors that enhance apoptosis, and repressed cell cycle genes, it may be useful in the prevention and therapy of breast cancer.&lt;br /&gt;&lt;strong&gt;Keywords:&lt;/strong&gt; actein • black cohosh • endoplasmic reticulum • micro-array • triterpene glycoside&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;span&gt;&lt;strong&gt;&lt;span&gt;International Journal of Cancer&lt;br /&gt;Volume 121, Issue 9, Pages 2073 - 2083 (1 November 2007)&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;strong&gt;&lt;span&gt;&lt;br /&gt;© 2007 Wiley-Liss, Inc.&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/3251846624293119876/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/3251846624293119876' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/3251846624293119876'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/3251846624293119876'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/09/breast-cancer-effect-of-actein.html' title='Breast cancer: Effect of actein'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-3505377974735182849</id><published>2007-09-18T05:39:00.000-07:00</published><updated>2007-09-18T05:44:12.124-07:00</updated><title type='text'>Colorectal cancer:  Cure models</title><content type='html'>&lt;strong&gt;Temporal trends in the proportion cured for cancer of the colon and rectum: &lt;span style=&quot;font-size:85%;&quot;&gt;A population-based study using data from the Finnish Cancer Registry&lt;/span&gt;&lt;/strong&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;color:#666666;&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;i&gt;Paul C. Lambert (1), Paul W. Dickman (2), Pia Österlund (3), Therese Andersson (2), Risto Sankila (4), Bengt Glimelius (5, 6)&lt;/i&gt;&lt;br /&gt;&lt;/span&gt;&lt;i&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;1) Department of Health Sciences, Centre for Biostatistics and Genetic Epidemiology, University of Leicester, Leicester, United Kingdom; 2) Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 3) Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; 4) Finnish Cancer Registry, Helsinki, Finland; 5) Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; 6) Department Oncology, Radiology and Clinical Immunology, University of Uppsala, Sweden&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;br /&gt;Colorectal cancer is the third most common cancer worldwide and the second most common cancer in Europe.&lt;br /&gt;Cumulative relative survival curves for both cancer of the colon and cancer of the rectum generally plateau after 6-8 years.&lt;br /&gt;When this occurs, “population” or “statistical” cure is reached. We analyzed data from the Finnish Cancer Registry over a 50-year period using methods that simultaneously estimate the proportion of patients cured of disease (the cure fraction) and the survival time distribution of the “uncured” group.&lt;br /&gt;Our primary aim was to investigate temporal trends in the cure fraction and median survival of the uncured by age group for both cancer of the colon and rectum. For both cancers, the cure fraction has increased dramatically over time for all age groups. However, the difference in the cure fraction between age groups has reduced over time, particularly for cancer of the colon.&lt;br /&gt;Median survival in the uncured has also increased over time in all age groups but there still remains an inverse relationship between age and median survival, with shorter median survival with increasing age.&lt;br /&gt;The reasons for these impressive increases in patient survival are complex, but are highly likely to be strongly related to many improvements in cancer care over this same time period.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;color:#3333ff;&quot;&gt;&lt;strong&gt;Keywords: &lt;/strong&gt;&lt;/span&gt;colorectal cancer • cure models • survival • colon cancer • rectum cancer&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;color:#000099;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;International Journal of Cancer&lt;br /&gt; Volume 121, Issue 9, Pages 2052 - 2059 (1 November 2007)&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;br /&gt;© 2007 Wiley-Liss, Inc.&lt;/span&gt;&lt;/strong&gt;&lt;br /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/3505377974735182849/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/3505377974735182849' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/3505377974735182849'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/3505377974735182849'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/09/colorectal-cancer-cure-models.html' title='Colorectal cancer:  Cure models'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-2374842311277875411</id><published>2007-09-14T07:44:00.000-07:00</published><updated>2007-09-14T07:50:25.161-07:00</updated><title type='text'>The risk of stomach cancer</title><content type='html'>&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiw4sXWU60vK3LL-602vI2ga7Z6XdKnjqpLg1f_-fnb5fwYuZ_b9rD9gNvPT3RjnP6CxW5MyaQRNpJPsT_nM1Mk7TzwNONmag2UopuHy4Qo4OJw5bfCx1OYY2yTAugmbR_0MR09UasoUkc/s1600-h/risk+of+stomach+cancer+.jpeg&quot;&gt;&lt;img id=&quot;BLOGGER_PHOTO_ID_5110072251308902642&quot; style=&quot;FLOAT: left; MARGIN: 0px 10px 10px 0px; CURSOR: hand&quot; alt=&quot;&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiw4sXWU60vK3LL-602vI2ga7Z6XdKnjqpLg1f_-fnb5fwYuZ_b9rD9gNvPT3RjnP6CxW5MyaQRNpJPsT_nM1Mk7TzwNONmag2UopuHy4Qo4OJw5bfCx1OYY2yTAugmbR_0MR09UasoUkc/s200/risk+of+stomach+cancer+.jpeg&quot; border=&quot;0&quot; /&gt;&lt;/a&gt; &lt;strong&gt;Genetic polymorphisms in alcohol metabolism, alcohol intake and the risk of stomach cancer in Warsaw, Poland&lt;/strong&gt;&lt;br /&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;em&gt;&lt;/em&gt;&lt;/span&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;em&gt;Fang Fang Zhang (1), Lifang Hou (2), Mary Beth Terry (3), Jolanta Lissowska (4), Alfredo Morabia (5), Jinbo Chen (6), Meredith Yeager (7), Witold Zatonski (4), Stephen Chanock (7), Wong-Ho Chow (8)&lt;br /&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;1) Department of Epidemiology, School of Public Health, University of North Texas Health Science Center, Fort Worth, TX; 2) Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL; 3) Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; 4) Division of Cancer Epidemiology and Prevention, Cancer Center and M. Sklosowska-Curie Institute of Oncology, Warsaw, Poland; 5) Center for the Biology of Natural Systems, Queens College-CUNY, Flushing, NY; 6) Department of Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, Philadelphia, PA; 7) Core Genotyping Facility, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD; 8) Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD&lt;br /&gt;&lt;/span&gt;&lt;/em&gt;&lt;br /&gt;Genetic variations increasing blood levels of acetaldehyde, the first metabolite of alcohol, refrain their carriers from drinking alcohol but may also put them at increased risk of cancer because of the mutagenic and carcinogenic effect of acetaldehyde. &lt;/span&gt;&lt;/div&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C&gt;T, Ex3+23A&gt;G, Ex3+58A&gt;T and Ex9+77A&gt;G), ADH1C (Ex8-56A&gt;G and Ex6-14G&gt;A) and ALDH2 (Ex1+82A&gt;G), on levels of alcohol drinking and susceptibility of stomach cancer. We found that among control subjects frequency of alcohol drinking varied by alcohol metabolizing genotype. &lt;/span&gt;&lt;/div&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;In particular, the weekly consumption of individuals carrying the AA, GA and GG genotypes of ALDH2 Ex1+82A &gt;G polymorphism were 3.75, 2.26 and 1.53 drinks, respectively (p= 0.04). &lt;/span&gt;&lt;/div&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;However, none of the assessed polymorphisms in these 3 genes had a measurable effect on stomach cancer risk. &lt;/span&gt;&lt;/div&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;When stratified by ALDH2 Ex1+82A&gt;G polymorphism, alcohol-related increases in stomach cancer risk were restricted to individuals with the AG/GG genotypes, with a more than 2-fold risk among daily drinkers (OR = 2.63, 95% CI = 1.00-6.88) and 3-fold risk (OR = 3.66, 95% CI = 1.19-11.24) among those with 40 or more drink-years. &lt;/span&gt;&lt;/div&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;In summary, our results suggested that the ALDH2 Ex1+82 G allele may be functionally deficient in eliminating acetaldehyde and discourage alcohol drinking. Furthermore, heavy drinkers of alcohol who were genetically prone to accumulate acetaldehyde may face an increased risk of stomach cancer.&lt;br /&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;br /&gt;&lt;div align=&quot;justify&quot;&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;strong&gt;Keywords:&lt;/strong&gt; stomach cancer • alcohol metabolism • genetic polymorphism&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;a href=&quot;http://www3.interscience.wiley.com/cgi-bin/jhome/29331&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;International Journal of Cancer&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;br /&gt;Volume 121, Issue 9, Pages 2060 - 2064 (1 November 2007)&lt;br /&gt;© 2007 Wiley-Liss, Inc.&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/2374842311277875411/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/2374842311277875411' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/2374842311277875411'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/2374842311277875411'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/09/risk-of-stomach-cancer.html' title='The risk of stomach cancer'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiw4sXWU60vK3LL-602vI2ga7Z6XdKnjqpLg1f_-fnb5fwYuZ_b9rD9gNvPT3RjnP6CxW5MyaQRNpJPsT_nM1Mk7TzwNONmag2UopuHy4Qo4OJw5bfCx1OYY2yTAugmbR_0MR09UasoUkc/s72-c/risk+of+stomach+cancer+.jpeg" height="72" width="72"/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6822263006341973987.post-1725765070031556823</id><published>2007-09-12T04:11:00.000-07:00</published><updated>2007-09-12T04:23:36.499-07:00</updated><title type='text'>Risk of Cancers of the upper digestive tract</title><content type='html'>&lt;strong&gt;Pipe smoking and cancers of the upper digestive tract&lt;/strong&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;color:#666666;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;Giorgia Randi (1, 2), Lorenza Scotti (1), Cristina Bosetti (1), Renato Talamini (3), Eva Negri (1), Fabio Levi (4), Silvia Franceschi (5), Carlo La Vecchia (1, 2)&lt;br /&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;color:#666666;&quot;&gt;&lt;i&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;1) Department of Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; 2) Istituto di Statistica Medica e Biometria G.A. Maccacaro, Università degli Studi di Milano, Milan, Italy; 3) Servizio di Epidemiologia e Biostatistica, Centro di Riferimento Oncologico, Aviano, Italy; 4) Unité d&#39;épidémiologie du cancer, Institut Universitaire de Médicine Sociale et Préventive, Université de Lausanne, Lausanne, Switzerland; 5) International Agency for Research on Cancer, Lyon, France&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;br /&gt;Pipe smoking has been related to the risk of cancers of the upper digestive and respiratory tract, but quantification of the risk for exclusive pipe smokers is still limited.&lt;br /&gt;To analyse the association between exclusive pipe smoking and cancers of the upper digestive tract, we used data from a series of case-control studies conducted in Italy and Switzerland between 1984 and 1999.&lt;br /&gt;After excluding cigarette and cigar smokers, 41 male oral and pharyngeal cancer cases, 52 male oesophageal cancer cases and 1,032 male controls were included in the present analysis.&lt;br /&gt;Odds ratios (OR) of cancers were estimated by the mean of unconditional multivariate logistic regression, including terms for age, study centre, education, body mass index, and alcohol drinking.&lt;br /&gt;Compared to never smokers, exclusive pipe smokers had an OR of 8.7 [95% confidence intervals (CI): 4.0-18.9] of all upper digestive tract cancers. The OR was 12.6 for oral and pharyngeal and 7.2 for oesophageal cancer. Pipe smokers who were also heavy alcohol drinkers had an OR of 38.8 (95% CI: 13.6-110.9) as compared to never smokers and light drinkers.&lt;br /&gt;Thus, pipe smoking and heavy alcohol drinking appears to interact at least on a multiplicative model.&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;Keywords:&lt;/strong&gt; digestive cancer • pipe smoking • case-control study • risk factors&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;color:#3333ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;International Journal of Cancer&lt;br /&gt; Volume 121, Issue 9, Pages 2049 - 2051 (1 November 2007)&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;span style=&quot;font-size:85%;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-size:78%;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color:#3333ff;&quot;&gt;© 2007 Wiley-Liss, Inc.&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://popularoncology.blogspot.com/feeds/1725765070031556823/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/6822263006341973987/1725765070031556823' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/1725765070031556823'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6822263006341973987/posts/default/1725765070031556823'/><link rel='alternate' type='text/html' href='http://popularoncology.blogspot.com/2007/09/risk-of-cancers-of-upper-digestive.html' title='Risk of Cancers of the upper digestive tract'/><author><name>Helen Sulicovska</name><uri>http://www.blogger.com/profile/00355455787800951747</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry></feed>